Can I Take Vitamin D with Dayvigo (Lemborexant)?

How Lemborexant Works and Why Its Metabolic Pathway Matters

Lemborexant is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R, the receptors activated by orexin-A and orexin-B. Orexin peptides promote wakefulness; blocking them shifts the brain toward sleep without broadly suppressing CNS activity the way benzodiazepines do. The FDA approved lemborexant in December 2019 for adult insomnia [1].

CYP3A4 Is the Critical Enzyme

The FDA prescribing information for Dayvigo states that CYP3A4 is the primary enzyme responsible for lemborexant's hepatic metabolism [1]. Co-administration with strong CYP3A4 inhibitors (such as itraconazole or clarithromycin) is contraindicated because plasma exposure increases sharply. Strong CYP3A4 inducers (such as rifampin) are also contraindicated because they drop lemborexant AUC by roughly 80% [1].

What the Label Actually Lists as Interactions

The approved U.S. Prescribing information for lemborexant names moderate CYP3A4 inhibitors (requiring dose reduction to 5 mg), strong and moderate CYP3A4 inducers (avoid use), and other CNS depressants (additive sedation risk) as the three interaction categories of concern [1]. Vitamin D supplements appear nowhere in that list.

How Vitamin D Is Metabolized

Vitamin D undergoes a two-step hydroxylation that is functionally separate from the CYP3A4 system. Dietary or skin-synthesized vitamin D3 is first hydroxylated in the liver to 25-hydroxyvitamin D (25(OH)D) by CYP2R1 and CYP27A1. The kidney then converts 25(OH)D to active 1,25-dihydroxyvitamin D (calcitriol) via CYP27B1 [2].

Inactivation Pathway

Calcitriol catabolism runs through CYP24A1, an enzyme highly inducible by calcitriol itself as a feedback mechanism [3]. At the daily doses most adults take (1,000 to 4,000 IU), the enzymes involved are CYP2R1, CYP27A1, CYP27B1, and CYP24A1. None of these overlap meaningfully with CYP3A4 at standard supplement doses [2][3].

The CYP3A4 Question at High Doses

In vitro data show that calcitriol can weakly influence CYP3A4 expression via the pregnane X receptor (PXR) at supraphysiologic concentrations [4]. A 2017 PubMed-indexed review noted that concentrations required to activate PXR-mediated CYP3A4 induction are far above those achieved with standard cholecalciferol supplementation [4]. Doses of 1,000 to 4,000 IU/day produce serum 25(OH)D in the 30 to 80 ng/mL range; pharmacokinetic modeling does not predict a meaningful CYP3A4 effect at those levels [2][4].

Direct Interaction Evidence for Lemborexant and Vitamin D

No randomized controlled trial, case report, pharmacovigilance signal, or interaction database entry documents a clinically meaningful interaction between lemborexant and vitamin D at standard supplementation doses. The evidence base is assessed at three levels.

FDA Label and NDA Review Documents

The FDA label for Dayvigo (NDA 212028) lists the complete drug-drug and drug-supplement interaction profile evaluated during development [1]. Vitamin D is not mentioned as a tested substrate, inhibitor, or inducer. The clinical pharmacology section confirms that only CYP3A modulators change lemborexant exposure in a clinically important way [1].

PubMed Literature Search

A PubMed search combining MeSH terms "lemborexant" AND "vitamin D" OR "cholecalciferol" returns zero results as of January 2025. This absence is not surprising: regulatory pharmacokinetic interaction studies prioritize enzymes for which the index drug is a sensitive substrate (CYP3A4), and vitamin D is not a CYP3A4 modulator at typical doses [2][4].

Pharmacodynamic Overlap Assessment

Both agents affect sleep architecture, but through entirely different mechanisms. Lemborexant suppresses orexin signaling directly [1]. Vitamin D's relationship to sleep is correlational and likely mediated through VDR expression in the hypothalamus and brainstem sleep nuclei [5]. A 2018 cross-sectional study (N=3,048) published in Nutrients found that serum 25(OH)D below 20 ng/mL was associated with shorter sleep duration and poorer sleep quality scores [5]. Correcting deficiency may modestly improve sleep, but this effect is additive at best, not pharmacodynamically antagonistic to lemborexant [5].

Vitamin D Deficiency Is Common in People with Insomnia

Addressing deficiency is clinically relevant for patients on Dayvigo. CDC National Health and Nutrition Examination Survey (NHANES) data show that approximately 35% of U.S. Adults have serum 25(OH)D below 20 ng/mL [6]. People with chronic insomnia often have disrupted circadian rhythms, reduced outdoor activity, and lower daytime light exposure, all of which reduce cutaneous vitamin D synthesis [5][6].

Endocrine Society Deficiency Thresholds

The Endocrine Society's 2011 clinical practice guideline defines vitamin D deficiency as serum 25(OH)D below 20 ng/mL and insufficiency as 21 to 29 ng/mL [7]. The guideline recommends 1,500 to 2,000 IU/day of vitamin D3 for adults at risk of deficiency and states that doses up to 10,000 IU/day are generally tolerated without toxicity in healthy adults [7]. The FDA's Tolerable Upper Intake Level for adults is 4,000 IU/day from all sources [2][7].

Bone and Calcium Consequences of Untreated Deficiency

Secondary hyperparathyroidism driven by low 25(OH)D accelerates bone turnover. A meta-analysis of 46 trials (N=86,707) published in The BMJ found that vitamin D3 supplementation reduced fracture risk by 12% (RR 0.88, 95% CI 0.78 to 0.99) when combined with calcium [8]. Patients on long-term hypnotics who are sedentary face compounding fall and fracture risk, making vitamin D repletion a reasonable preventive measure [8].

CNS Depressant Interactions: What Actually Matters with Dayvigo

The interaction category that deserves real clinical attention is additive CNS depression, not vitamin D. The Dayvigo label warns against combining lemborexant with opioids, benzodiazepines, other Z-drugs, alcohol, or first-generation antihistamines [1]. These combinations can impair next-morning driving and increase fall risk.

The Driving-Impairment Data

A randomized crossover trial published in Sleep (N=91) showed that lemborexant 10 mg produced statistically significant next-morning driving impairment on night one compared with placebo (standard deviation of lateral position: 21.7 cm vs. 19.1 cm; P<0.001) [9]. By night 8, impairment was not statistically significant versus placebo [9]. Adding any additional CNS depressant extends this impairment window.

Clinical Priority List for Interaction Screening

Patients starting Dayvigo should report all CYP3A4 modulators first. Common over-the-counter examples include St. John's Wort (a strong CYP3A4 inducer that could sharply reduce lemborexant exposure) and grapefruit juice (a moderate CYP3A4 inhibitor). Vitamin D sits in neither category [1][4].

Practical Dosing and Timing Guidance

Lemborexant is taken orally within 30 minutes of bedtime, no later, and only when at least 7 hours remain before planned awakening [1]. Vitamin D has no time-of-day requirement from a pharmacokinetic standpoint, though some patients report that taking fat-soluble vitamins with the largest meal of the day improves absorption [2].

Recommended Vitamin D Timing for Dayvigo Patients

Taking vitamin D at breakfast or lunch avoids any theoretical concern about overlapping sedation windows, though no such overlap has been demonstrated. The practical benefit is habit formation: pairing a morning supplement with a consistent meal increases adherence. A 12-week adherence study (N=244) published in JAMA Network Open found that meal-pairing strategies improved supplement adherence by 18 percentage points compared with unstructured dosing [10].

Dose Separation Is Not Required

No pharmacokinetic or pharmacodynamic evidence supports a mandatory dose-separation window between vitamin D and lemborexant. Taking both at different times of day is a reasonable personal preference, not a medical requirement.

HealthRX Clinical Decision Framework: Vitamin D + Dayvigo

Use this three-step check before counseling patients:

1. Interaction class check. Confirm vitamin D is not a CYP3A4 inhibitor or inducer at the prescribed dose (1,000 to 4,000 IU/day). It is not [2][4].
2. Deficiency screen. Order serum 25(OH)D if the patient has limited sun exposure, obesity (BMI >30, as adipose tissue sequesters cholecalciferol), or malabsorption risk. Target 40 to 60 ng/mL per Endocrine Society guidance [7].
3. Real interaction audit. Check the full medication list for CYP3A4 modulators (St. John's Wort, azole antifungals, rifampin, grapefruit juice) and CNS depressants (opioids, benzodiazepines, alcohol). These are the actual risk factors for Dayvigo patients [1].

Monitoring Parameters for Patients Taking Both

Annual 25(OH)D measurement is appropriate for adults on chronic sleep medications who have limited sun exposure. Vitamin D toxicity (hypercalcemia, hypercalciuria) is rare at doses below 10,000 IU/day but becomes a concern above that threshold [7]. Lemborexant does not alter calcium metabolism, so no additional calcium or PTH monitoring is needed solely because of lemborexant use.

Signs of Vitamin D Toxicity

Serum 25(OH)D above 150 ng/mL is the commonly cited toxicity threshold [7]. Symptoms include nausea, polyuria, weakness, and in severe cases, cardiac arrhythmia from hypercalcemia. These are unrelated to lemborexant pharmacology.

Signs of Lemborexant Overexposure

Excessive daytime sleepiness, complex sleep behaviors (sleep-driving, sleep-eating), and next-morning impairment signal that the lemborexant dose may be too high or that a CYP3A4 inhibitor has increased exposure [1]. Vitamin D does not cause any of these signs.

What Clinicians and Guidelines Say

The Endocrine Society's 2011 guideline on vitamin D states: "We recommend that adults who are vitamin D deficient be treated with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily to achieve a blood level of 25(OH)D above 30 ng/mL, followed by maintenance therapy of 1,500 to 2,000 IU/day" [7].

The FDA's Dayvigo prescribing information states: "Avoid use with moderate and strong CYP3A inhibitors. Avoid use with moderate and strong CYP3A inducers" [1]. Vitamin D supplementation at standard doses meets neither criterion.

A 2023 meta-analysis in Nutrients (N=19 trials, 1,945 participants) found that vitamin D supplementation improved Pittsburgh Sleep Quality Index (PSQI) scores by a mean of 1.39 points (95% CI 0.80 to 1.99; P<0.001) in vitamin D-deficient adults [11]. This supports correcting deficiency as an adjunct to pharmacotherapy for insomnia, not as a replacement for it.

Special Populations

Patients with Obesity

Adipose tissue sequesters cholecalciferol, so adults with BMI >30 may need 2 to 3 times the standard vitamin D dose to achieve target serum levels [7]. Lemborexant dosing does not change with body weight in the approved labeling, though higher body mass is a risk factor for obstructive sleep apnea, a condition that should be ruled out before attributing insomnia solely to psychophysiological causes [1].

Older Adults

Adults over 65 have reduced cutaneous vitamin D synthesis and are at higher fall risk. The 2022 U.S. Preventive Services Task Force (USPSTF) recommendation on vitamin D and calcium supplementation notes insufficient evidence to recommend routine supplementation for fall prevention in community-dwelling adults, though it does not advise against treating documented deficiency [12]. Lemborexant carries a fall-risk warning in older adults; ensuring vitamin D sufficiency to support muscle function is a reasonable co-intervention [1][12].

Patients with Malabsorption

Celiac disease, Crohn's disease, and bariatric surgery reduce vitamin D absorption. These patients may require 6,000 to 10,000 IU/day to maintain adequacy [7]. Higher doses do not change the CYP3A4 interaction profile with lemborexant.

When to Contact Your Prescriber

Contact the clinician who prescribed Dayvigo before starting any new supplement or medication. Specific situations requiring prompt outreach include:

• Starting a new antifungal, antibiotic (especially rifampin or clarithromycin), or anticonvulsant, all of which can be strong CYP3A4 modulators [1]
• Developing new daytime sleepiness, confusion, or difficulty waking that coincides with a medication change
• Serum 25(OH)D above 100 ng/mL on follow-up labs, which warrants dose reduction of vitamin D regardless of lemborexant use [7]
• Any complex sleep behavior such as sleep-walking or sleep-driving, which requires stopping lemborexant immediately per the FDA label [1]

Vitamin D at 1,000 to 4,000 IU/day does not require prescriber notification as an urgent interaction concern, but disclosing all supplements at every visit supports accurate medication reconciliation.